Bedfont Scientific Ltd Win Medway Business of the Year
       By: Jason Smith
Posted: 2011-01-15 07:12:46
Bedfont Scientific Ltd have won Business of the Year in the 2010 Medway Business of the Year Awards.

In the hotly contested top award at the ceremony, the innovative, achievement driven approach of Bedfont made the difference.

One of the judges, Susan Jennings, Partner and Head of Corporate, Furley Page Solicitors, said: "I was particularly impressed with Bedfont Scientific which is succeeding in making life saving devices widely accessible through clever and innovative designs and international distribution networks. Bedfont has managed to transform a huge and expensive piece of machinery into a hand-held device which should have a major impact on monitoring for those with asthma. Medway should be proud to have businesses like Bedfont committed to the area and we were delighted to be able to recognise its talent and achievement in awarding it Medway Business of the Year."

The NObreath exhaled nitric oxide monitor was showcased as Bedfonts newest innovation and caught the judges eyes due to its complexity and ability to open up gold standard asthma management to a much wider audience.

Collecting the award on behalf of Bedfont, Jason Smith, Sales & Marketing Manager, said: It is very rewarding to be apart of a company who is leading the way in developing non-invasive methods of saving and improving the quality of people’s lives. Winning this award shows that all our ward work and dedication does not go un-noticed by the outside world.

Bedfont Managing Director, Trevor Smith said: 2010 has been a huge year for Bedfont, from climbing mountains for charity, to overcoming technical challenges with our focus on product development. We have become more profitable in a harsh economy, and saving lives along the way what an incredible story of success! I’m looking forward to seeing what 2011 brings.

Established for over 30 years, Bedfont produce quality products catering to customers’ needs and are proud to be at the forefront of breath and medical gas monitoring technology.

For more information on Bedfont Scientific Ltd visit www.bedfont.com/

or call the UK Sales Team on +44 (0)1622 851122
The very name Cancer is not an unknown to the mankind as each and every year a notable number of people die due to this harmful disease. In spite of a hectic and tough scheduled research work there is such anti cancer drug yet to be found. The scientists and the researchers are putting their hard core try to get some fruitful result. The process of cancer drug discovery is not at all an easy one. It is a fact that kinase inhibitors help the progress of the work. The positive response found through some products of kinase family is really appreciable and the research is on fast move with a proper kinase profiling.

Basically cancer is a disease caused due to the out of control cell growth. Some cells affected by cancerous virus follows a certain level of growth that can not be controlled. Such grown up cells are the actual cause of cancer that leads to death for millions of people each and every year. Several kinds of kinase inhibitors help to in terms of this growth of cancerous cells from various dimensions. Almost hundreds of cancerous cells are there and each and every cell is identified with some affected cells.

Cancerous cells harm the body while they divide into numerous lumps transforms into several tumors without any control. There is an exception in the process in terms of leukemia. Such tumors can be very harmful for the digestive, nervous and circulatory systems while releasing hormones. They demonstrate very limited level of growth. These are certain factors that can be instigated through the proper experiments with kinase inhibitors. The products are undoubtedly very rare in the market and the demand is very high. A proper supplier is also necessary so that there is no such pause in the developmental process.

Various components of the CDK inhibitor are on trial under the supervision of a number of scientists and researchers. A tough and experimental work is going on with clinical trails. This experimental process is important in terms of finding remedies related with leukemia, melanoma and other solid tumors. Even such components are important to find out solution for the patients with more specific types of cancer. Actually the Cyclin-dependent kinase inhibitor is a chemical reducing functionaries of CDKs. It is a fact there is no medically approved anti-cancer drugs yet but these inhibitors on the process of developmental trials just because they get more and more positive responses.

Most of the cancerous tumors are caused due to the over activeness and CDK-inhibiting proteins. Basically they are the most important cancer targeted inhibitors. The constant genetic studies reveal the various specs behind these protein inhibitors on specified tissues or cells. AT-7519 is such a discovered product that gives some positive and very active responses on human cancerous cells. It is a novel small molecule multi-cyclin-dependent kinase inhibitor. It induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

Let us move to another kind of kinase category and that is JNK inhibitor. It stands for a stress-activated protein kinase modulating various pathways with a wide variety of disease states. Among the many CC-401 is the most effective one to provide an instant remedy to the patients though the trial is going on. The best thing is that positive responses are coming up in terms of such research work. Due to its extreme positive result in the cancer drug discovery process kinase inhibitors are well known to each and every person in the pharmaceutical industry. Kinase includes a large number of engymes regulating various activities of other proteins. Even they are capable enough to instigate other activities of different cells.
Trackback url: https://press.abc-directory.com/press/6990